Rxisk Requests Reports From Trans Individuals About Medical Treatment Side Effects

NEWS

A drug side effects reporting site, RxISK, has called for submissions of reports of side effects from transgender medicine.

A description of the RxISK site:

RxISK is owned and operated by Data Based Medicine Americas Ltd. (DBM), based in Toronto, Canada.

It is run by a group of high-profile medical experts with international reputations in early drug-side-effect detection and risk mitigation, pharmacovigilance, and patient-centered care.

It’s call for feedback around trans medicine side effects titled “Transgender Meds: A Call for Reports” reviews information reflecting the same concerns examined on the GHQ website.

The specific medical treatments they are asking for information on are as follows:

This post is an invitation to report on drugs prescribed to transgender people. These include cross-sex hormones – testosterone for women, estrogen and progesterone for men, hormone-blocking agents like Lupron given to children with gender dysphoria to stop the physical changes of puberty, and other drugs like finasteride, spironolactone and birth-control pills prescribed to manage the transition from male to female or female to male.

Some of the reasons they cite for the request are the increasing numbers of youth being medically treated and the changing demographics and protocol around this:

Until recently, drugs and surgery were choices facing a small number of transgender people, mainly adults. Only when a child’s longstanding “gender identity disorder” persisted into their teens would clinics discuss physical treatments. For adult patients, most required months of counseling and at least a year of “social transition” to living in their preferred gender role.

They go on to list many of the medical risks and side effects covered in our topic on medical consequences.

REFERENCES:

RxISK. (2019, July 8). Transgender Meds: A Call for Reports. Retrieved from https://rxisk.org/transgender-meds-a-call-for-reports/